Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nakanishi Inc. (7716.T)
JPY3,010.00
+0.00 (+0.00%)
JP JPX Healthcare Medical - Instruments & Supplies
Address
700 Shimohinata 322-8666
Kanuma, JP
Kanuma, JP
CEO
Eiichi Nakanishi
IPO
2000-07-21
ISIN JP3642500007
Description
Nakanishi Inc. operates as an international producer and supplier of an extensive array of goods for the dental, industrial, and medical markets. Their comprehensive dental offerings feature turbines, clinical micromotors, contra-angles, in addition to products supporting built-in and mobile dentistry, oral hygiene, endodontics, surgical needs, dental laboratory work, and general maintenance. Furthermore, the company offers motor spindles and micro grinding tools within its industrial segment. Nakanishi Inc. caters to a wide spectrum of industries, including automotive, micromechanics, electronics, healthcare, die/mold manufacturing, aerospace, and energy. The company was established in 1930 and maintains its headquarters in Kanuma, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY3,010.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
220.6K
Beta
0.10
Float Shares
54.52M
Free Float %
65.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.90% | +4.89% | +4.11% | +15.49% | +39.19% | +47.22% | +55.81% | -1.90% | +27.25% | +143.40% | +2,102.81% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3,010.00
DCF (Unlevered)
5,665.28
+88.2%
DCF (Levered)
3,886.18
+29.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.28
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+5.4% Q1'26: +21.3% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-128.4% Q1'26: +816.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+12.3% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+17.4% ★ Q1'26: +20.8% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+10.8% ★ Q1'26: +15.2% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-1.6% ★ Q1'26: -1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×1.35× ★ Q1'26: 1.39× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 7 EPS Ana. |
Dec 2027 7 Rev. Ana. 7 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
31.86B
est: 31.20B (+2.1%)
|
31.83B
est: 32.00B (-0.5%)
|
34.34B
est: 34.80B (-1.3%)
|
36.54B
est: 37.50B (-2.6%)
|
35.42B
est: 35.91B (-1.4%)
|
33.06B
est: 31.40B (+5.3%)
|
44.86B
est: 43.70B (+2.6%)
|
48.67B
est: 49.05B (-0.8%)
|
59.69B
est: 69.99B (-14.7%)
|
77.04B
est: 76.66B (+0.5%)
|
81.18B
est: 81.08B (+0.1%)
|
90.50B
89.10B – 91.99B
+11.6% YoY
|
95.79B
94.27B – 98.50B
+5.8% YoY
|
101.12B
101.12B – 101.12B
+5.6% YoY
|
106.13B
104.46B – 108.51B
+5.0% YoY
|
111.54B
109.80B – 114.05B
+5.1% YoY
|
| EBITDA |
10.64B
est: 11.70B (-9.0%)
|
9.27B
est: 12.00B (-22.7%)
|
10.72B
est: 13.05B (-17.9%)
|
11.27B
est: 14.07B (-19.9%)
|
11.05B
est: 13.47B (-17.9%)
|
10.35B
est: 11.78B (-12.1%)
|
15.61B
est: 16.39B (-4.7%)
|
17.49B
est: 18.40B (-4.9%)
|
17.71B
est: 21.21B (-16.5%)
|
20.46B
est: 23.23B (-11.9%)
|
19.90B
est: 24.57B (-19.0%)
|
27.42B
27.00B – 27.87B
+11.6% YoY
|
29.02B
28.56B – 29.84B
+5.8% YoY
|
30.64B
30.64B – 30.64B
+5.6% YoY
|
32.15B
31.65B – 32.88B
+5.0% YoY
|
33.80B
33.27B – 34.56B
+5.1% YoY
|
| EBIT |
9.60B
est: 9.99B (-3.9%)
|
8.24B
est: 10.25B (-19.6%)
|
9.53B
est: 11.15B (-14.5%)
|
9.73B
est: 12.01B (-19.0%)
|
9.30B
est: 11.50B (-19.1%)
|
8.54B
est: 10.06B (-15.1%)
|
13.75B
est: 14.00B (-1.8%)
|
15.39B
est: 15.71B (-2.0%)
|
14.22B
est: 17.13B (-17.0%)
|
14.60B
est: 18.77B (-22.2%)
|
14.09B
est: 19.85B (-29.0%)
|
22.15B
21.81B – 22.52B
+11.6% YoY
|
23.45B
23.08B – 24.11B
+5.8% YoY
|
24.75B
24.75B – 24.75B
+5.6% YoY
|
25.98B
25.57B – 26.56B
+5.0% YoY
|
27.31B
26.88B – 27.92B
+5.1% YoY
|
| Net Income |
6.20B
est: 5.66B (+9.7%)
|
5.30B
est: 5.49B (-3.4%)
|
7.34B
est: 6.56B (+11.9%)
|
7.59B
est: 7.49B (+1.3%)
|
7.10B
est: 6.52B (+9.0%)
|
6.46B
est: 6.17B (+4.6%)
|
10.10B
est: 9.47B (+6.6%)
|
12.47B
est: 12.00B (+3.9%)
|
22.80B
est: 21.76B (+4.8%)
|
8.58B
est: 10.69B (-19.8%)
|
-2.40B
est: 9.03B (-126.6%)
|
11.67B
11.04B – 12.30B
+29.2% YoY
|
12.79B
10.93B – 14.38B
+9.6% YoY
|
13.74B
11.05B – 15.79B
+7.4% YoY
|
15.20B
14.89B – 15.64B
+10.6% YoY
|
16.32B
15.98B – 16.79B
+7.4% YoY
|
| SGA |
7.70B
est: 7.95B (-3.1%)
|
8.23B
est: 8.16B (+0.8%)
|
8.59B
est: 8.87B (-3.1%)
|
9.06B
est: 9.56B (-5.2%)
|
9.25B
est: 9.15B (+1.1%)
|
8.07B
est: 8.00B (+0.8%)
|
10.14B
est: 11.14B (-9.0%)
|
11.72B
est: 12.50B (-6.2%)
|
16.68B
est: 19.68B (-15.2%)
|
21.88B
est: 21.56B (+1.5%)
|
30.50B
est: 22.80B (+33.8%)
|
25.45B
25.06B – 25.87B
+11.6% YoY
|
26.94B
26.51B – 27.70B
+5.8% YoY
|
28.44B
28.44B – 28.44B
+5.6% YoY
|
29.84B
29.38B – 30.52B
+5.0% YoY
|
31.37B
30.88B – 32.07B
+5.1% YoY
|
| EPS |
71.22
est: 66.63 (+6.9%)
|
61.15
est: 64.63 (-5.4%)
|
84.75
est: 77.33 (+9.6%)
|
87.59
est: 88.29 (-0.8%)
|
81.97
est: 76.77 (+6.8%)
|
74.49
est: 72.70 (+2.5%)
|
116.73
est: 111.60 (+4.6%)
|
145.48
est: 140.13 (+3.8%)
|
267.62
est: 255.78 (+4.6%)
|
101.37
est: 127.37 (-20.4%)
|
-28.70
est: 106.54 (-126.9%)
|
141.20
132.10 – 147.20
+32.5% YoY
|
155.70
130.80 – 172.10
+10.3% YoY
|
168.50
132.30 – 189.00
+8.2% YoY
|
181.89
178.18 – 187.21
+7.9% YoY
|
195.28
191.30 – 200.99
+7.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
5.31B
OE per share TTM
62.53
Owner's Yield
2.13%
Maintenance CapEx ratio
149.41%
Maint CapEx / Avg PPE
38.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
6.46M
Shares Outstanding
83.05M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eiichi Nakanishi | President, Group Chief Executive Officer & Representative Director | 148M | male |
| Kensuke Nakanishi | Executive Vice President, Chief Operating Officer & Representative Director | 85M | male |
| Daisuke Suzuki | Corporate Vice President & Group Chief Financial Officer | — | male |
| Masataka Suzuki | Senior Managing Executive Officer & Director | — | male |
| Masatoshi Akiya | Head of Corporate Communication | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7716.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
